

**Listing of All Claims Including Current Amendments**

1. (Currently amended) A method ~~of using for~~ delivering a peptide into the major histocompatibility complex (MHC) class I antigen processing pathway of an anti-gen presenting cell to elicit a cytotoxic T lymphocyte (CTL) response, comprising contacting said cell with a mutant of ~~EtxB or CtxB~~ E. coli heat labile enterotoxin B (EtxB) or cholera toxin B (CtxB) covalently linked to said peptide, -comprising de-livering an agent to a target cell wherein said the mutant has a mutation in the region spanning amino acid residues E-51 – I58 of the  $\beta 4$ - $\alpha 2$  loop of said EtxB or CtxB and wherein said mutant has GM-1 binding activity; but wherein ~~the~~ said mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.
2. (Currently amended) The method of claim 1 wherein ~~the agent is selected from the group consisting of a peptide or protein of interest (POI)~~ peptide is derivable from a protein of interest (POI) or an antigen.
3. (Currently amended) The method ~~according to~~ of claim 2 wherein ~~the agent is linked to a membrane translocating or fusogenic peptide~~ antigen is selected from the group consisting of a viral antigen, a bacterial antigen, a parasitic antigen; and a tumour associated antigen (TAA) .
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)

10. (Previously presented) The method of claim 1 wherein the mutant comprises a mutation at amino acid residues 51, 56 and/or 57 of the  $\beta 4$ - $\alpha 2$  loop.
11. (Previously presented) The method of claim 1 or claim 10 wherein the mutant comprises a H57A or H57S mutation.
12. (Currently amended) A method of preparing a medicament comprising providing a mutant of ~~EtxB or CtxB~~ E. coli heat labile enterotoxin B (EtxB) or cholera toxin B (CtxB) in the preparation of a medicament, wherein the mutant has a mutation in the region spanning amino acid residues E-51 – I58 of the  $\beta 4$ - $\alpha 2$  loop of said EtxB or CtxB and is capable of delivering an exogenous peptide into the major histocompatibility complex Class I antigen processing and presentation pathways to elicit a cytotoxic T lymphocyte response.
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled).
17. (Currently amended) A method of delivering an agent ~~a peptide using a mutant to a target cell~~ to the MHC class I antigen processing pathway of an antigen presenting cell, wherein the method comprises:
  - (i) providing ~~a target~~ an antigen presenting cell;
  - (ii) contacting the cell with a mutant of ~~EtxB or CtxB~~ E. coli heat labile enterotoxin B (EtxB) or cholera toxin B (CtxB) covalently linked to the peptide; the mutant having a mutation in the region spanning amino acid residues E51 – I58 of the  $\beta 4$ - $\alpha 2$  loop of EtxB or CtxB ~~wherein the mutant has~~ and having GM-1 binding activity; but ~~wherein the mutant has a reduced im-~~

munogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB; and

- (iii) monitoring for the presence of the agent peptide in the ~~target~~ antigen pre-senting cell.
18. (Currently amended) ~~A— The method according to of~~ claim 17 ~~wherein the agent is delivered to a vesicular compartment, and/or cytosol and/or nucleus and/or an organelle of the target cell.~~, further comprising the step of monitoring the elicitation of a cytotoxic T lymphocyte (CTL) response.
19. (Canceled)
20. (Canceled)
21. (Currently amended) A kit for delivering ~~an agent to a target cell~~ a peptide to the MHC class I antigen processing pathway of an antigen presenting cell wherein the kit comprises:
- (i) a mutant of ~~EtxB or CtxB~~ E. coli heat labile enterotoxin B (EtxB) or cholera toxin B (CtxB) covalently linked to the peptide; the mutant having a mutation in the region spanning amino acid residues E51 – I58 of the  $\beta 4$ - $\alpha 2$  loop of EtxB or CtxB ~~wherein the mutant has~~ and having GM-1 binding activity; but ~~wherein the mutant has a~~ reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB[[:]].
  - (ii) ~~an agent for delivery to the target cell; and optionally~~
  - (iii) ~~means for detecting the location of the agent in the target cell.~~
22. (Canceled)
23. (Canceled)
24. (Canceled)

25. (Canceled)

Please add the following claim:

26. (New) The kit of claim 21, further comprising means for detecting the location of the peptide in the antigen presenting cell